ENTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.90%

Insider Buying (Last 12 Months): $56,274.47

Insider Selling (Last 12 Months): $0.00

Entera Bio Insider Trading History Chart

Entera Bio Share Price & Price History

^$1.69

▼ -0.05 (-2.87%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

J.P. Morgan’s DIRE Warning

From Behind the Markets | Ad

When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."

Click here to see why Wall Street is in PANIC mode >>>

Entera Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2024	Haya Taitel	Director	Buy	9,500	$0.99	$9,405.00	35,115
1/10/2024	Haya Taitel	Director	Buy	7,615	$0.77	$5,863.55	25,615
12/22/2023	Miranda Jayne Toledano	CEO	Buy	23,952	$0.71	$17,005.92	110,752
8/21/2023	Sean Ellis	Director	Buy	40,000	$0.60	$24,000.00	102,100
4/4/2023	Miranda Jayne Toledano	CEO	Buy	30,000	$1.01	$30,300.00	86,800
11/11/2022	Miranda Jayne Toledano	CEO	Buy	50,000	$0.53	$26,500.00	56,800
11/11/2022	Sean Ellis	Director	Buy	30,000	$0.53	$15,900.00	62,100
7/21/2022	Sean Ellis	Director	Buy	14,900	$1.64	$24,436.00	32,100
1/19/2022	Ramesh Ratan	CFO	Buy	10,000	$2.44	$24,400.00
1/18/2022	Ron Mayron	Director	Buy	7,000	$2.80	$19,600.00
1/13/2022	Yonatan Malca	Director	Buy	7,232	$2.74	$19,815.68

J.P. Morgan’s DIRE Warning

From Behind the Markets | Ad

When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."

Click here to see why Wall Street is in PANIC mode >>>

SEC Filings (Institutional Ownership Changes) for Entera Bio (NASDAQ:ENTX)

14.11% of Entera Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Entera Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/20/2024	Virtu Financial LLC	22,040	$37K	0.0%	N/A	0.000%
2/14/2023	RA Capital Management L.P.	295,966	$0.22M	0.0%	-85.8%	1.028%
11/14/2022	RA Capital Management L.P.	2,082,372	$2.17M	0.0%	-11.5%	7.229%
1/31/2022	Altium Wealth Management LLC	11,830	$33K	0.0%	N/A	0.050%
1/28/2022	ARK Investment Management LLC	690,922	$1.95M	0.0%	+1.2%	2.915%
8/17/2021	Knoll Capital Management LLC	2,484,275	$14.86M	7.8%	+38.7%	10.482%
8/16/2021	RA Capital Management L.P.	2,353,000	$14.07M	0.2%	N/A	9.928%
8/13/2021	Geode Capital Management LLC	17,597	$0.11M	0.0%	N/A	0.074%
8/11/2021	Susquehanna Fundamental Investments LLC	14,400	$86K	0.0%	N/A	0.061%
6/14/2021	Knoll Capital Management LLC	1,791,363	$6.83M	4.4%	+2.9%	7.558%
5/18/2021	Millennium Management LLC	38,611	$0.15M	0.0%	N/A	0.163%
5/14/2021	XTX Topco Ltd	11,559	$44K	0.0%	N/A	0.101%
5/13/2021	Renaissance Technologies LLC	120,407	$0.46M	0.0%	+66.8%	1.053%
2/24/2021	Virtu Financial LLC	31,314	$34K	0.0%	N/A	0.274%
2/10/2021	Renaissance Technologies LLC	72,186	$78K	0.0%	N/A	0.632%
10/20/2020	Wedbush Securities Inc.	121,616	$0.15M	0.0%	+305.3%	1.064%
8/10/2020	Phoenix Holdings Ltd.	37,400	$66K	0.0%	-46.1%	0.000%

Data available starting January 2016

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Today's Range

Now: $1.69

$1.65

$1.75

50 Day Range

MA: $2.02

$1.64

$2.44

52 Week Range

Now: $1.69

$0.52

$3.35

Volume

61,448 shs

Average Volume

160,341 shs

Market Capitalization

$60.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Who are the company insiders with the largest holdings of Entera Bio?: Entera Bio's top insider shareholders include:
Miranda Jayne Toledano (CEO)
Sean Ellis (Director)
Haya Taitel (Director)
Learn More about top insider investors at Entera Bio.